Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.

Area of Science:

• Molecular biology
• Angiogenesis research
• Endothelial cell biology

Background:

• Osteoprotegerin (OPG) is a molecule that protects endothelial cells from apoptosis and promotes neovascularization.
• The roles of OPG and its ligands, receptor activator of nuclear factor-kappaB ligand (RANKL) and tumor necrosis factor-related apoptosis inducing ligand (TRAIL), in angiogenesis are not fully understood.

Purpose of the Study:

• To investigate the role of OPG, RANKL, and TRAIL in microvessel formation using the rat aortic ring model.
• To elucidate the mechanisms by which OPG and RANKL regulate endothelial cell proliferation, apoptosis, and signaling pathways involved in angiogenesis.

Main Methods:

• Rat aortic ring model of angiogenesis.
• Assessment of angiogenic sprouting and endothelial cell proliferation.
• Induction of endothelial cell apoptosis.
• Analysis of ERK1/2 and Akt phosphorylation in human umbilical vein endothelial cells (HUVECs).

Main Results:

• OPG significantly increased angiogenic sprouting and endothelial cell proliferation in the rat aortic ring model.
• RANKL potently inhibited both basal and vascular endothelial growth factor-induced angiogenesis, reduced endothelial cell proliferation, and induced apoptosis.
• TRAIL did not affect angiogenesis on its own but inhibited OPG's pro-angiogenic effects.
• OPG induced ERK1/2 and Akt phosphorylation in HUVECs, while RANKL had no effect on these pathways.

Conclusions:

• OPG acts as a positive regulator of microvessel formation and angiogenesis.
• RANKL functions as an angiogenic inhibitor by negatively regulating endothelial cell proliferation, promoting apoptosis, and affecting cellular signaling.
• These findings highlight the opposing roles of OPG and RANKL in angiogenesis and suggest potential therapeutic targets for vascular diseases.